SCHEMBL6420125

SCHEMBL6420125

COc1ccc(C(=O)N2c3ccccc3C(n3c4ccccc4c4ccccc43)CC2CCCCC(=O)O)cc1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.43
POLB P06746 1/20 0.39
F12 P00748 1/20 0.38
P2RY1 P47900 1/20 0.38
PTGIR P43119 1/20 0.37
BCHE P06276 4/20 0.37
ACHE P22303 4/20 0.37
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
MAPT P10636 1/20 0.36
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6419699 0.92 TP53 (0.39) MCL1POLBP2RY1KMT2AMAPT
SCHEMBL6421823 0.91 MCL1 (0.41) MCL1POLBF12P2RY1BCHE
SCHEMBL6419648 0.91 MCL1 (0.41) MCL1POLBF12P2RY1BCHE
SCHEMBL6420083 0.91 MCL1 (0.43) MCL1F12P2RY1PTGIRBCHE
SCHEMBL6420214 0.90 MCL1 (0.41) MCL1POLBF12P2RY1PTGIR
SCHEMBL6420042 0.89 P2RY1 (0.49) POLBP2RY1PDE4BPTGDR2KMT2A
SCHEMBL6421449 0.89 MCL1 (0.42) MCL1F12P2RY1BCHEACHE
SCHEMBL6647217 0.88 MCL1 (0.41) MCL1F12P2RY1PTGIRBCHE
SCHEMBL6421447 0.87 MCL1 (0.41) MCL1F12P2RY1PTGIRBCHE
SCHEMBL6423893 0.86 MCL1 (0.40) MCL1F12P2RY1BCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6930104-B2 Heterocyclic derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-16 US disclosed
US-20040157850-A1 Novel heterocyclic derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-08-12 US disclosed
EP-1382598-A1 NOVEL HETEROCYCLIC DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2004-01-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157850-A1 Novel heterocyclic derivatives APP, BACE1, PSEN1 MCL1 3567/4885POLB 4822/4885F12 564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.